Conjugate Vaccine Market Report – Research, Industry Analysis Reports and Market Demands

Global (United States, European Union and China) Conjugate Vaccine Market Research Report 2019-2025

Request for Sample of this report

Buy now

Table of Content

1 Report Overview

1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
- 1.3.1 Global Conjugate Vaccine Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Monovalent
- 1.3.3 Multivalent
1.4 Market Segment by Application
- 1.4.1 Global Conjugate Vaccine Market Share by Application (2019-2025)
- 1.4.2 Hospitals
- 1.4.3 Clinics
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends

2.1 Global Conjugate Vaccine Market Size
- 2.1.1 Global Conjugate Vaccine Revenue 2014-2025
- 2.1.2 Global Conjugate Vaccine Sales 2014-2025
2.2 Conjugate Vaccine Growth Rate by Regions
- 2.2.1 Global Conjugate Vaccine Sales by Regions 2014-2019
- 2.2.2 Global Conjugate Vaccine Revenue by Regions 2014-2019
2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers

3 Market Share by Manufacturers

3.1 Conjugate Vaccine Sales by Manufacturers
- 3.1.1 Conjugate Vaccine Sales by Manufacturers 2014-2019
- 3.1.2 Conjugate Vaccine Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
- 3.2.1 Conjugate Vaccine Revenue by Manufacturers (2014-2019)
- 3.2.2 Conjugate Vaccine Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Conjugate Vaccine Market Concentration Ratio (CR5 and HHI)
3.3 Conjugate Vaccine Price by Manufacturers
3.4 Key Manufacturers Conjugate Vaccine Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Conjugate Vaccine Market
3.6 Key Manufacturers Conjugate Vaccine Product Offered
3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Sales and Revenue for Each Type
- 4.1.1 Monovalent Sales and Revenue (2014-2019)
- 4.1.2 Multivalent Sales and Revenue (2014-2019)
4.2 Global Conjugate Vaccine Sales Market Share by Type
4.3 Global Conjugate Vaccine Revenue Market Share by Type
4.4 Conjugate Vaccine Price by Type

5 Market Size by Application

5.1 Overview
5.2 Global Conjugate Vaccine Sales by Application

6 United States

6.1 United States Conjugate Vaccine Breakdown Data by Company
6.2 United States Conjugate Vaccine Breakdown Data by Type
6.3 United States Conjugate Vaccine Breakdown Data by Application

7 European Union

7.1 European Union Conjugate Vaccine Breakdown Data by Company
7.2 European Union Conjugate Vaccine Breakdown Data by Type
7.3 European Union Conjugate Vaccine Breakdown Data by Application

8 China

8.1 China Conjugate Vaccine Breakdown Data by Company
8.2 China Conjugate Vaccine Breakdown Data by Type
8.3 China Conjugate Vaccine Breakdown Data by Application

9 Rest of World

9.1 Rest of World Conjugate Vaccine Breakdown Data by Company
9.2 Rest of World Conjugate Vaccine Breakdown Data by Type
9.3 Rest of World Conjugate Vaccine Breakdown Data by Application
9.4 Rest of World Conjugate Vaccine Breakdown Data by Countries
- 9.4.1 Rest of World Conjugate Vaccine Sales by Countries
- 9.4.2 Rest of World Conjugate Vaccine Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia

10 Company Profiles

11 Value Chain and Sales Channels Analysis

11.1 Value Chain Analysis
11.2 Sales Channels Analysis
- 11.2.1 Conjugate Vaccine Sales Channels
- 11.2.2 Conjugate Vaccine Distributors
11.3 Conjugate Vaccine Customers

12 Market Forecast

12.1 Global Conjugate Vaccine Sales and Revenue Forecast 2019-2025
12.2 Global Conjugate Vaccine Sales Forecast by Type
12.3 Global Conjugate Vaccine Sales Forecast by Application
12.4 Conjugate Vaccine Forecast by Regions
- 12.4.1 Global Conjugate Vaccine Sales Forecast by Regions 2019-2025
- 12.4.2 Global Conjugate Vaccine Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
  - 14.1.1.1 Research Programs/Design
  - 14.1.1.2 Market Size Estimation
  - 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
  - 14.1.2.1 Secondary Sources
  - 14.1.2.2 Primary Sources
14.2 Author Details

Description

Conjugate vaccines are formed by covalently bonding a weak antigen to the strong antigen. It boosts the hosts’ immune response. Conjugate vaccines are germ specific and can identify targeted germ only, so it can be used as a preventative measure to provide additional protection. Conjugate vaccines are used to treat Hib (Haemophilus influenzae type b) disease, Hepatitis B, HPV (Human papillomavirus), Whooping cough (part of the DTaP combined vaccine), Pneumococcal disease, Meningococcal disease, and Shingles.
The rising occurrence of diseases caused by microorganisms, increasing awareness about prevention of infectious diseases, and an increasing number of regulatory approvals to the vaccines are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market.
In 2019, the market size of Conjugate Vaccine is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Conjugate Vaccine.

This report studies the global market size of Conjugate Vaccine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Conjugate Vaccine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
GlaxoSmithKline
Pfizer
Merck
Sanofi Pasteur
CSL
Emergent BioSolutions
Johnson & Johnson
Medimmune
Astellas Pharma
Serum Institute of India
Bavarian Nordi
Mitsubishi Tanabe Pharma
Daiichi Sankyo Company
Fablife
SutroVax
Sinovac Biotech

Market Segment by Product Type
Monovalent
Multivalent

Market Segment by Application
Hospitals
Clinics

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Conjugate Vaccine status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Conjugate Vaccine manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Conjugate Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025